IQVIA (IQV) Set to Release Quarterly Earnings on Tuesday

IQVIA (NYSE:IQV) is expected to be releasing its Q3 2026 results before the market opens on Tuesday, October 27th. Analysts expect IQVIA to post earnings of $3.25 per share and revenue of $4.37 billion for the quarter. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Individuals can check the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Tuesday, October 27, 2026 at 9:00 AM ET.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.03 by $0.12. The business had revenue of $4.37 billion for the quarter, compared to analysts’ expectations of $4.30 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%. The firm’s quarterly revenue was up 8.7% compared to the same quarter last year. During the same period in the previous year, the business posted $2.81 EPS. On average, analysts expect IQVIA to post $11.56 EPS for the current fiscal year and $12.93 EPS for the next fiscal year.

IQVIA Price Performance

NYSE IQV opened at $265.72 on Tuesday. The company has a market cap of $43.74 billion, a PE ratio of 32.97, a price-to-earnings-growth ratio of 2.32 and a beta of 1.17. IQVIA has a 52 week low of $154.50 and a 52 week high of $277.40. The company has a quick ratio of 0.71, a current ratio of 0.71 and a debt-to-equity ratio of 2.18. The firm’s 50-day simple moving average is $261.23 and its two-hundred day simple moving average is $213.85.

Insider Activity at IQVIA

In other IQVIA news, insider Keriann Cherofsky sold 558 shares of the firm’s stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total value of $136,827.18. Following the completion of the transaction, the insider owned 2,989 shares in the company, valued at $732,932.69. This trade represents a 15.73% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider W. Richard Staub sold 5,500 shares of IQVIA stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $232.68, for a total value of $1,279,740.00. Following the transaction, the insider directly owned 13,312 shares of the company’s stock, valued at $3,097,436.16. The trade was a 29.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 15,581 shares of company stock worth $3,796,021 in the last 90 days. 1.70% of the stock is owned by company insiders.

Analyst Ratings Changes

Several research firms have recently weighed in on IQV. UBS Group initiated coverage on shares of IQVIA in a research note on Wednesday, September 30th. They issued a “buy” rating and a $345.00 target price for the company. TD Cowen boosted their price target on shares of IQVIA from $233.00 to $288.00 and gave the company a “buy” rating in a research report on Wednesday, July 29th. Wall Street Zen upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a research note on Saturday, September 12th. Deutsche Bank Aktiengesellschaft set a $240.00 price target on shares of IQVIA in a research note on Thursday, July 9th. Finally, William Blair raised shares of IQVIA to a “strong-buy” rating in a report on Tuesday, July 28th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $276.00.

IQVIA Company Profile

IQVIA Holdings Inc is a global provider of technology, analytics and contract research services for the life sciences industry. The company helps pharmaceutical, biotechnology and medical device organizations develop, commercialize and improve products by combining healthcare data with advanced analytics, consulting and technology-enabled services.

Its offerings include clinical research and trial management, real-world evidence, healthcare data and analytics, regulatory and safety services, technology platforms, and commercial solutions.